Photobiomodulation for Prevention of Radiodermatitis in Women With Breast Cancer Undergoing Adjuvant Radiotherapy
Radiodermatitis
About this trial
This is an interventional prevention trial for Radiodermatitis focused on measuring radiotherapy, Radiodermatitis, photobiomodulation, breast cancer
Eligibility Criteria
Inclusion Criteria:
- Women over 18 years of age
- Stage I to IIIC breast cancer
- Have an indication for adjuvant radiotherapy treatment at HCIII/INCA.
Exclusion Criteria:
- have a previous diagnosis of cancer
- underwent surgery and/or chemotherapy outside the Institution
- were unable to respond to the questionnaires
- were unable to receive photobiomodulation due to acute infections will be excluded.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Placebo Comparator
Experimental
Group control
Intervention group
Patients will receive applications with the LED board turned off without light activation. Applications will be performed within 1 hour after radiotherapy, three times a week, by a trained team, consisting of physical therapists and physical therapy students, and the application time will be the same as in the intervention group. Women will be instructed to maintain specific home exercises for the upper limbs, which are part of the routine of the physiotherapy sector since the first postoperative day at the HCIII/INCA, in addition to their usual physical activities.
At the beginning of radiotherapy treatment, all HCIII/INCA patients are instructed by the nursing team in this sector to use the DNA® ointment provided at the institution and to take proper skin care. Patients identified by the nursing staff with some degree of radiodermatitis undergo treatment with silver sulfadiazine and, if necessary, radiotherapy can be interrupted so that the skin regenerates.